Validation Study of the Italian Version of the "Assessment of Life Habits 4.0" Scale (LIFE-H) for Measuring Participation in Children With Disabilities Aged 5 to 13 Years

BACKGROUNG In Italy there are still few translated and validated instruments to assess participation.

In the field of pediatric rehabilitation, among the tools available internationally, one of the most comprehensive and widely used is the Assessment of Life Habits, or LIFE-H, now in its 4.0 version. The LIFE-H scale was originally developed in French and implemented by the International Network on the Disability Creation Process - INDPC, also known as the Quebec Model or Handicap Creation Process.

Internationally, the "LIFE-H" scale has been translated and validated in several languages. The scale is among the most comprehensive and detailed instruments in the literature: it consists of 90 items (life habits), divided into 12 domains, 6 of which are for regular activities (e.g., communication and mobility), and 6 for social roles (responsibility and interpersonal relationships).

A study of Italian translation and cultural adaptation of the LIFE-H scale 4.0 for children aged 5 to 13 years, was carried out during 2020-2021.

The scale and its related user manual in Italian version have also been insert into the platform of the Canadian originator company "Réseau international sur le Processus de production du handicap" - RIPPH).

AIM The goal of the study is to assess the intra- and inter-rater reliability, internal consistency and construct validity of the scale in its Italian version.

METHOD Participants will be recruited from the pediatric rehabilitation centers of Toscana Centro , AOU Meyer IRCCS and AORN Santobono-Pausilipon Subjects interviewed will be caregivers of children with disabilities between the ages of 5 and 13 years. Care-givers of children with physical, sensory and cognitive disabilities, regardless of diagnosis, will be included in the study, as per the scale's user manual.

First Part Step 1: Presentation of the project through informational documentation to pediatric rehabilitation physical therapists of the territorial services of Toscana Centro and AOU Meyer IRCCS, who will identify candidate families for the study.

Step 2: Collection of informed consent by the investigating physical therapist in the referral area.

Step 3: TEST: Administration of the LIFE-H 4.0 / 5-13 years scale by an investigator (FT 1). As stipulated among the modes of administration, the questionnaire will be completed by the reference person or parent of the child with support from the experimenter. The administration will be done via video call on Google Meet platform, which platform is deemed most suitable in terms of use for families.

Step 4 : RETEST: After an interval of 15 days, second administration of the questionnaire will be carried out in the same manner and by the same experimenter.

Step 5 : Analysis and comparison of the collected data. Second part Step 6: Making contact with subjects who had adhered to both phases of the study (as indicated in the informed consent signed in step one) and re-enrollment through informational documentation to pediatric rehabilitation physical therapists from the territorial services of Toscana Centro, AOU Meyer IRCCS, and AORN Santobono-Pausilipon, who will identify candidate families for the study.

Step 7: Collection of informed consent from the investigating physical therapist in the target area.

Step 8: TEST: Administration of the LIFE-H 4.0 / 5-13 years scale by an investigator (FT 3). As stipulated among the modes of administration, the questionnaire will be completed by the reference person or parent of the child with support from the experimenter. The administration will be done via video call on Google Meet which platform is deemed most suitable in terms of family use.

Step 9: RETEST: Administration of the LIFE-H 4.0 / 5-13 years scale by an experimenter (FT 4) 15 days apart in the same manner.

Step 10: To complete the validation process (Construct Validity), the PEM-CY questionnaire will be provided to parents participating in the second phase of the study. The instrument was chosen, among the few available in the Italian language, because of features in common with the Life-H scale. The caregivers will be able to fill out the paper version of the questionnaire themselves. The latter will be kept within the child's medical record; the investigators will only be informed of the final score of the questionnaire.

step 11: analysis and comparison of collected data SAMPLE SIZING AND STATISTICAL METHODS OF DATA ANALYSIS With respect to the required sample size, contacts have been made with the Canadian authors of the LIFE-H scale (International Network on the Disability Creation Process - INDPC), who suggest a minimum minimum sample size of 30 subjects. Also taking into consideration other scale validation articles, we therefore plan to enroll 30 subjects for Phase 1 (intra-operator concordance and internal consistency) and 130 subjects for Phase 2 (inter-operator concordance and construct validity of construct). Analysis of the results of the LIFE-H questionnaire

Study Overview

• Status: Recruiting
• Conditions: Validation Study

• Study Type: Observational
• Enrollment (Estimated): 180

Contacts and Locations

• Study Contact: Name: Silvia Paoli, Pediatric Physiotherapist MSc; Phone Number: 039-0555662954; Email: silvia.paoli@meyer.it
• Study Contact Backup: Name: Elena Biagini, pediatric physiotherapist MSc; Email: elena.biagini2@uslcentro.toscana.it

Study Locations

• Italy
  • Florence, Italy, 50139
    • Recruiting
    • Meyer Children Hospital IRCCS
    • Contact: silvia paoli, Pediatric Physiotherapist MCs; Phone Number: 039-0555662954; Email: silvia.paoli@meyer.it
    • Contact: Elena Prato, pediatric physiotherapist MSc; Phone Number: 039-0555662953; Email: elena.prato@meyer.it
    • Principal Investigator: silvia paoli, pediatric Phisiotherapist MSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Caregivers of children with disabilities between the ages of 5 and 13 years. Care-givers of children with physical, sensory and cognitive disabilities, regardless of diagnosis, will be included in the study, as per the scale's user manual.

Description

Inclusion Criteria:

• caregivers of children with physical, sensory, cognitive disabilities between the ages of 5 and 13 years.

Exclusion Criteria:

• Parents who do not master the Italian language
• Absence of signed informed consent from parents

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intra/inter-operator concordance (test-retest) will be estimated using the intraclass correlation coefficient (ICC)	Will consider poor scores between 0 and 0.20; fair between 0.21 and 0.40; moderate between 0, 41 and 0.60 ; good between 0.61 and 0.80; excellent between 0.81 and 1	Baseline and after 15 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Internal consistency will be evaluated with Cronbach's Alph	A result ≥ of 0.7 will be considered relevant	Baseline and after 15 days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Construct validity will be assessed by r Rho	Will consider as strong correlation with r Rho ≥ 0.7	Baseline and after 15 days

Collaborators and Investigators

• Sponsor: Meyer Children's Hospital IRCCS
• Investigators: Principal Investigator: silvia paoli, pediatric Phisiotherapist MSc, Meyer Children's Hospital IRCCS

Study record dates

Study Major Dates

• Study Start (Actual): February 23, 2024
• Primary Completion (Estimated): April 1, 2026
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: February 25, 2025
• First Submitted That Met QC Criteria: February 25, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 4, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: LFH01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No